Rituximab Induced Remission in Patients With Chronic Inflammatory Demyelinating Polyneuropathy — StellaPhase 3 — Large-scale testing across thousands of people, comparing the new treatment against current standard treatments.
Age range
18 Years – 80 Years
Last updated December 2024